FOXP3 is a direct target of miR15a/16 in umbilical cord blood regulatory T cells

Bone Marrow Transplantation

Volumn 49, Issue 6, 2014, Pages 793-799

  Liu, X ^a   Robinson, S N ^a   Setoyama, T ^a   Tung, S S ^a   D'Abundo, L ^a   Shah, M Y ^a   Yang, H ^a,a   Yvon, E ^a   Shah, N ^a   Konopleva, M ^a   Garcia Manero, G ^a   McNiece, I ^a   Rezvani, K ^a   Calin, G A ^a   Shpall, E J ^a   Parmar, S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ENZYME INHIBITOR; MICRORNA; MICRORNA 15A; MICRORNA 16; PEPTIDASE INHIBITOR 16; PROTEIN P53; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; CARRIER PROTEIN; CTLA4 PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; GLYCOPROTEIN; MIRN15 MICRORNA, HUMAN; MIRN16 MICRORNA, HUMAN; PI16 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEMETHYLATION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE REACTION; MOUSE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; UMBILICAL CORD BLOOD; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CYTOLOGY; DISEASE MODEL; FETUS BLOOD; GENE EXPRESSION; GENE SILENCING; GENETICS; IMMUNOLOGY; METABOLISM; MIXED LYMPHOCYTE CULTURE; NONOBESE DIABETIC MOUSE; SCID MOUSE; SITE DIRECTED MUTAGENESIS; TUMOR SUPPRESSOR GENE; XENOGRAFT;

ANIMALS; CARRIER PROTEINS; CELLS, CULTURED; CTLA-4 ANTIGEN; DISEASE MODELS, ANIMAL; FETAL BLOOD; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; GENES, P53; GLYCOPROTEINS; GRAFT VS HOST DISEASE; HETEROGRAFTS; HUMANS; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED NOD; MICE, SCID; MICRORNAS; MUTAGENESIS, SITE-DIRECTED; T-LYMPHOCYTES, REGULATORY;

EID: 84902078409     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2014.57     Document Type: Article

References (38)

1. Sakaguchi S. Regulatory T cells: history and perspective. Methods Mol Biol 2011; 707: 3-17.
2. Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011; 117: 1061-1070.
3. Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117: 3921-3928.
4. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4 (+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002; 99: 3493-3499.
5. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003; 9: 1144-1150.
6. Hippen KL, Harker-Murray P, Porter SB, Merkel SC, Londer A, Taylor DK et al. Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. Blood 2008; 112: 2847-2857.
7. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-1061.
8. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330-336.
9. Zheng Y, Josefowicz SZ, Kas A, Chu TT, Gavin MA, Rudensky AY. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 2007; 445: 936-940.
10. Liston A, Lu LF, O'Carroll D, Tarakhovsky A, Rudensky AY. Dicer-dependent microRNA pathway safeguards regulatory T cell function. J Exp Med 2008; 205: 1993-2004.
11. Zhou X, Jeker LT, Fife BT, Zhu S, Anderson MS, McManus MT et al. Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med 2008; 205: 1983-1991.
12. Ranganathan P, Heaphy CE, Costinean S, Stauffer N, Na C, Hamadani M et al. Regulation of acute graft-versus-host disease by microRNA-155. Blood 2012; 119: 4786-4797.
13. Rouas R, Fayyad-Kazan H, El Zein N, Lewalle P, Rothe F, Simion A et al. Human natural Treg microRNA signature: role of microRNA-31 and microRNA-21 in FOXP3 expression. Eur J Immunol 2009; 39: 1608-1618.
14. Lu LF, Thai TH, Calado DP, Chaudhry A, Kubo M, Tanaka K et al. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 2009; 30: 80-91.
15. Sadlon TJ, Wilkinson BG, Pederson S, Brown CY, Bresatz S, Gargett T et al. Genome-wide identification of human FOXP3 target genes in natural regulatory T cells. J Immunol 2010; 185: 1071-1081.
16. Nicholson IC, Mavrangelos C, Bird DR, Bresatz-Atkins S, Eastaff-Leung NG, Grose RH et al. PI16 is expressed by a subset of human memory Treg with enhanced migration to CCL17 and CCL20. Cell Immunol 2012; 275: 12-18.
17. Parmar S, Robinson SN, Komanduri KSt, John L, Decker W, Xing D et al. Ex vivo expanded umbilical cord blood T cells maintain naive phenotype and TCR diversity. Cytotherapy 2006; 8: 149-157.
18. Parmar SLS, Tung SS, Robinson SN, Rodriguez G, Cooper LJN, Yang H et al. Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease. Cytotherapy 2013; 16: 90-100.
19. Sato T, Deiwick A, Raddatz G, Koyama K, Schlitt HJ. Interactions of allogeneic human mononuclear cells in the two-way mixed leucocyte culture (MLC): influence of cell numbers, subpopulations and cyclosporin. Clin Exp Immunol 1999; 115: 301-308.
20. Reddy V, Hill GR, Pan L, Gerbitz A, Teshima T, Brinson Y et al. G-CSF modulates cytokine profile of dendritic cells and decreases acute graft-versus-host disease through effects on the donor rather than the recipient. Transplantation 2000; 69: 691-693.
21. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C (T) method. Nat Protoc 2008; 3: 1101-1108.
22. Diegelmann J, Olszak T, Goke B, Blumberg RS, Brand S. A novel role for interleukin-27 (IL-27) as mediator of intestinal epithelial barrier protection mediated via differential signal transducer and activator of transcription (STAT) protein signaling and induction of antibacterial and anti-inflammatory proteins. J Biol Chem 2012; 287: 286-298.
23. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple onco-genic activities. Nat Med 2008; 14: 1271-1277.
24. Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S et al. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA 2011; 305: 59-67.
25. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003; 115: 787-798.
26. Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org resource: targets and expression. Nucleic Acids Res 2008; 36: D149-D153.
27. Gibbs GM, Roelants K, O'Bryan MK. The CAP superfamily: cysteine-rich secretory proteins, antigen 5, and pathogenesis-related 1 proteins-roles in reproduction, cancer, and immune defense. Endocr Rev 2008; 29: 865-897.
28. Diez-Roux G, Banfi S, Sultan M, Geffers L, Anand S, Rozado D et al. A high-resolution anatomical atlas of the transcriptome in the mouse embryo. PLoS Biol 2011; 9: e1000582.
29. Ye J, Huang X, Hsueh EC, Zhang Q, Ma C, Zhang Y et al. Human regulatory T cells induce T-lymphocyte senescence. Blood 2012; 120: 2021-2031.
30. Sawant DV, Wu H, Kaplan MH, Dent AL. The Bcl6 target gene microRNA-21 promotes Th2 differentiation by a T cell intrinsic pathway. Mol Immunol 2013; 54: 435-442.
31. Baron U, Floess S, Wieczorek G, Baumann K, Grutzkau A, Dong J et al. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur J Immunol 2007; 37: 2378-2389.
32. Balaguer F, Link A, Lozano JJ, Cuatrecasas M, Nagasaka T, Boland CR et al. Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res 2010; 70: 6609-6618.
33. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyl-transferases 3A and 3B. Proc Natl Acad Sci USA 2007; 104: 15805-15810.
34. Klein ME, Lioy DT, Ma L, Impey S, Mandel G, Goodman RH. Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA. Nat Neurosci 2007; 10: 1513-1514.
35. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008; 322: 1695-1699.
36. Bachmann MF, Kohler G, Ecabert B, Mak TW, Kopf M. Cutting edge: lymphopro-liferative disease in the absence of CTLA-4 is not T cell autonomous. J Immunol 1999; 163: 1128-1131.
37. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 2012; 30: 531-564.
38. Zheng SG, Wang JH, Stohl W, Kim KS, Gray JD, Horwitz DA. TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cells. J Immunol 2006; 176: 3321-3329.